MARKET

ALDX

ALDX

Aldeyra Therapeutics Inc
NASDAQ
0.7904
-0.1094
-12.16%
After Hours: 0.8001 +0.0097 +1.23% 16:41 10/14 EDT
OPEN
0.8800
PREV CLOSE
0.8998
HIGH
0.8990
LOW
0.7886
VOLUME
1.58M
TURNOVER
--
52 WEEK HIGH
5.93
52 WEEK LOW
0.7886
MARKET CAP
47.68M
P/E (TTM)
-2.0642
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ALDX last week (1005-1009)?
Weekly Report · 2d ago
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 10/06 21:05
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 10/05 17:05
Weekly Report: what happened at ALDX last week (0928-1002)?
Weekly Report · 10/05 10:17
Aldeyra Therapeutics: Neutral Rating Maintained Amid FDA Uncertainty; $2 Price Target Reaffirmed
TipRanks · 09/30 10:25
Aldeyra Therapeutics Price Target Maintained With a $2.00/Share by HC Wainwright & Co.
Dow Jones · 09/30 10:24
HC Wainwright & Co. Reiterates Neutral on Aldeyra Therapeutics, Maintains $2 Price Target
Benzinga · 09/30 10:14
Aldeyra Fights Back Against FDA Rejection, Dispute Plan Triggers Rally
Benzinga · 09/29 18:34
More
About ALDX
Aldeyra Therapeutics, Inc. is a biotechnology company focused on discovering therapies designed to treat immune-mediated and metabolic diseases. The Company's approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Its product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX 248, ADX-743, ADX-631, ADX-246, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated and metabolic diseases. Its late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa. ADX 629 is in Phase II clinical trials for moderate alcohol-associated hepatitis and Sjogren-Larsson Syndrome.

Webull offers Aldeyra Therapeutics Inc stock information, including NASDAQ: ALDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALDX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALDX stock methods without spending real money on the virtual paper trading platform.